AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03766282 — intervention group
Intervention type: DEVICE
Intervention: ECMO
Description: Extracorporeal membrane oxygenation (ECMO) temporarily supports patients with severe cardio-respiratory failure
Study NCT02176720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDOPA PET
Description: \[18F\]FDOPA radiopharmaceutical will be intravenousely injected for PET-CT scanning of the brain.
Study NCT01908881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Workshop
Description: The intervention consists in a group workshop (for up to 7 dyads with children aged between 6 and 12 months and two health care professional monitors) of four sessions of two hours each, held weekly. One of the sessions is characterized as including the fathers or other caregivers relevant to the upbringing of the children. Each session is structured around various activities that specifically deal with the skills associated with parental sensitivity and address relevant issues to child rearing, considering the development of the child.
Study NCT01908881 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: According to the screening carried out various interventions are offered by Primary Health Care centers (eg. home visits) in the Chile Crece Contigo Program. During pregnancy, if the mother is screened for positive psychosocial risk she would receive different interventions consisting in (usual care at Primary Health Care Centers): home visits, evaluation by social worker and planning interventions according to a multidisciplinary team.
Study NCT01908881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: According to the screening carried out various interventions are offered by Primary Health Care centers (eg. home visits) in the Chile Crece Contigo Program. During pregnancy, if the mother is screened for positive psychosocial risk she would receive different interventions consisting in (usual care at Primary Health Care Centers): home visits, evaluation by social worker and planning interventions according to a multidisciplinary team.
Study NCT04600011 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical and occupational therapy (PT/OT)
Description: Neurologic-specialized and -certified physical and occupational therapists will provide each participant with an initial in-person PT/OT evaluation/treatment session with oversight from a Movement Disorders Neurologist, followed by 4 virtual home visits with tele-PT/OT and care partner supervision every 2 weeks, and culminating with a final in-person evaluation, all with a focus on personalized training in core areas contributing to a patient's individual fall risk, much like in-person visits. Virtual home safety surveillance with the mobile virtual platform is an additional feature of this intervention that aims to optimize the home environment to reduce external factors contributing to fall risk.
Study NCT04600011 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Home Safety Evaluation (HSE)
Description: The VIRTUAL HOME SAFETY EVALUTIONS (HSE)-ONLY ARM where participants ONLY receive the virtual home safety evaluations and surveillance that are built into the original protocol of three of the four tele-OT visits that is being used in Arm 1. The study duration for Arm 2 is about 6 weeks of the primary intervention as described with 3-month and 6-month follow-up calls. The mobile virtual platform for Arm 2 is comprised of a tablet OR smartphone that will be guided through the home by the care partner only and not the patient.
Study NCT02362568 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Ultrasound cervical exploration
Description: The cervical ultrasound exploration will consist in the ultrasound measurement of the length between the hyoid bone and the skin and the length between the thyroid cartilage and the skin. The ultrasound cervical exploration will be performed in all patients admitted in the postoperative room after a planned surgery performed under general anesthesia.
Study NCT02969018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Study NCT01343901 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab
Description: Participants with mCRC and having exclusively liver or liver and lung metastases who were receiving bevacizumab as part of first line treatment for potentially resectable liver metastases as per treating physician's discretion will be observed. All concomitant medications as used in routine clinical practice are allowed.
Study NCT01181401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPF induction chemotherapy
Description: Docetaxel 75 mg/m2 d 1 Cis-platinum 75 mg/m2 d 1 5-FU 750 mg/m2/d c.i. d 1-4 Cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
Study NCT01181401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPF experimental
Description: Docetaxel 40 mg/m2 d 1+8 Cis-platinum 40 mg/m2 d 1+8 5-FU 1500 mg/m2/24h c.i. d 1+8 every 21 day for 3 cycles 2. Antibody therapy with: cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
Study NCT01181401 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Radiochemotherapy (HART)
Description: Hyperfractionated accelerated radiotherapy with concurrent Cisplatin and 5-Fluorouracil chemotherapy
Study NCT03945175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYDAYIS
Description: MYDAYIS treatment will be given at a minimum dose of 12.5mg/day and will increase in increments of 12.5mg, up to 37.5mg, based upon clinical response and tolerability.
Study NCT03945175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: During the two-week, placebo lead-in, all patients will receive 12.5mg of placebo at Visit 1 and Visit 2.
Study NCT01718912 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: metronidazole-nystatin oral rinse
Study NCT01081548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: 20 mg
Study NCT01081548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: 20 mg
Study NCT00572221 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Continuing Quality Improvement and Quality Assurance system
Description: The main intervention is a facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation.
Study NCT00572221 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CQI and QA System with Best-Practice Care Protocols
Description: A facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. Research clinical staff will also provide best-practice care protocols designed by our research team to address targeted problem conditions.
Study NCT01043042 — intervention group
Intervention type: OTHER
Intervention: No interventions will be used in this study
Description: No interventions will be used in this study
Study NCT02758405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.125% Bupivacaine plus fentanyl 2mcg/ml
Study NCT02758405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 0.125% Bupivacaine plus fentanyl 2mcg/ml
Study NCT02758405 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infusion pump
Description: Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
Study NCT04104269 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Heart rupture
Description: Free wall rupture and Ventricular septal rupture
Study NCT00865488 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADHEXIL
Description: Adhesions prevention
Study NCT04128787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG881 Formulation 1
Description: AG881 uncoated tablets
Study NCT04128787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG881 Formulation 2
Description: AG881 film-coated tablets
Study NCT04128787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole capsules
Study NCT00739271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early feeding
Study NCT00739271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: late feeding after bowel sounds return
Description: Traditional method
Study NCT04363216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Ascor® ascorbic acid 2-hour infusion daily (for 6 days), escalating dose (0.3g/kg, 0.6g/kg, 0.9g/kg).
Study NCT03946176 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Symbiotic
Description: HD patients follow a 8-weeks oral administration of the symbiotic supplement (2 bags/day)
Study NCT03946176 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: HD patients follow a 8-weeks oral administration of the placebo (2 bags/day)
Study NCT03946176 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: DVB cartridge
Description: On the last week of the symbiotic/placebo period, patients undergo 3 dialytic sessions with the DVB cartridge
Study NCT03946176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DVB cartridge
Description: On the last week of the symbiotic/placebo period, patients undergo 3 dialytic sessions with the DVB cartridge
Study NCT04022746 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography
Description: Undergo multiparametric MRI/MRE
Study NCT04022746 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo multiparametric MRI/MRE
Study NCT02315521 — intervention group
Intervention type: PROCEDURE
Intervention: Fetal Intervention for LUTO
Description: Fetal vesico-amniotic shunting placement consists in placing a shunt (stent) percutaneously from fetal bladder to the amniotic cavity under ultrasound guidance.~Fetal cystoscopy will be performed using a thin scope that will be introduced to the fetal bladder for evaluation of the cause of the obstruction and ablation of the posterior urethral valves.
Study NCT04020744 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: real-time fMRI based neurofeedback from the hippocampus
Description: During real-time fMRI neurofeedback, participants are trained to 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.
Study NCT04020744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: real-time fMRI based neurofeedback from the hippocampus
Description: During real-time fMRI neurofeedback, participants are trained to 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.
Study NCT01633645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 70 mg/m2 on day 1 of a 21-days treatment cycle for a maximum of 8 cycles
Study NCT01473953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide-depot
Description: Subjects will be randomised to receive a single dose of liraglutide-depot, at increasing dose levels, injected s.c./subcutaneously (under the skin). Progression to next dose level (max. 8) will be based on safety evaluation.
Study NCT01473953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will be randomised to receive a single dose of liraglutide-depot placebo, at increasing dose levels, injected s.c./subcutaneously (under the skin).
Study NCT00939718 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin B12
Description: Vitamin B12 injections containing methylcobalamin 1000 mcg given once every six months along with the routine antidepressant treatment.
Study NCT00939718 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12
Description: Vitamin B12 injections containing methylcobalamin 1000 mcg given once every six months along with the routine antidepressant treatment.
Study NCT03059628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Normative Feedback
Description: This PNF technique use information designed to correct normative misperceptions to reduce heavy drinking. Much of the alcohol consumption among college students stems from the fairly widespread perception that one's peers expect regular and sometimes extreme drinking participation (subjective drinking norms). The PNF approach is designed to counter this perception by giving students accurate figures on how much their peers actually drink (actual drinking norms). It also aims to improve students' understanding of alcohol use in general and the firmly established negative outcomes associated with short - and long-term patterns of excessive drinking.
Study NCT04112589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Quizartinib at different doses in the phase I (40mg-14 days; 60mg-14 days; 60mg-7days, 40mg-7days). RP2D in the phase II part.
Study NCT04112589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 intravenous days 1 to 4 of the cycle
Study NCT04112589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2 g/m 2 intravenous days 1 to 4 (1 g/m2 in patients older than 59) of the cycle
Study NCT04112589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: 10 mg/ 2 intravenous days 1 to 3 of the cycle
Study NCT04112589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycosylated G-CSF
Description: daily dose of 300 mcg/m 2 , from day -1 until day 5 of the cycle
Study NCT04288544 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Microalgae
Description: Open, monocentric intervention study in crossover design
Study NCT04288544 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Microalgae
Description: Open, monocentric intervention study in crossover design
Study NCT04288544 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3-fatty acid capsule
Description: Open, monocentric intervention study in crossover design
Study NCT04288544 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3-fatty acid capsule
Description: Open, monocentric intervention study in crossover design
Study NCT04288544 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sea fish
Description: Open, monocentric intervention study in crossover design
Study NCT02550769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TRANSANAL TOTAL MESORECTAL EXCISION
Description: The technique begins with the TEO equipment and a purse string 1 cm distal to the tumor. The dissection progresses in the posterior part until the laparoscopic TME field is reached. After the section of the rectum and TME transanal dissection, the anvil of the circular mechanical stapler is introduced through the TEO rectoscope. In the laparoscopic field, the mesosigma is sectioned at the point where the colon section is to be performed. The TEO rectoscope is withdrawn, and the bag containing the specimen is removed through the anus. The stapler is inserted. From the laparoscopic field, the strings of the purse are tightened and the purse is closed around the rectal stump with a clip. Then the stapler are joined to perform the anastomosis and a loop ileostomy is placed in the right flank.
Study NCT02550769 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic-LAR
Description: Standard laparoscopic low anterior resection of the rectum with total mesorectal excision and colorectal anastomosis
Study NCT00925743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel (XRP6258)
Description: * administered by IV infusion~* in addition to cisplatin treatment
Study NCT02772198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR T cells
Description: Autologous T cells activated and transduced with a chimeric antigen receptor targeting CD19
Study NCT02162576 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Propeller Health intervention
Description: The Propeller intervention works through the provision of information to patients and their providers. With the Propeller sensor device in place, each actuation of a patient's rescue inhaler is recorded with an automatic time stamp and geographic location. Actuation data are then securely transmitted to Propeller Health where the information is also compiled into individual reports via mobile apps, online dashboards, email reports and text message reminders that are returned to the patient. This communication provides an ongoing assessment of their management based on the national guidelines, together with personalized information to help encourage and support self-management. Each participant was invited to share reports with his or her healthcare provider, but this was not required.
Study NCT04441762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Ketorolac Tromethamine
Description: 30 mg ketorolac single dose
Study NCT04441762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Ketorolac Tromethamine
Description: 30 mg ketorolac single dose
Study NCT04144491 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotics are defined by the Food and Agricultural Organization (FAO)/WHO as live microorganisms, which when consumed in adequate amounts, confer a health benefit on the host. Lactobacillus rhamnosus GG (LGG) is the most documented probiotic bacteria, with many proven unique characteristics and therewith associated health benefits. No adverse effects of the consumption of LGG in healthy infants have been reported. The Lactobacillus rhamnosus yoba containing yoghurt drink, which is locally produced and subsequently consumed by resource-poor communities in rural Uganda has been described. The strain used in this intervention is a generic variant of LGG, called Lactobacillus rhamnosus yoba 2012. LGG is consumed as part of food all over the world, and is not a drug.~100ml of yoghurt containing Lactobacillus rhamnosus yoba 2012 will be consumed 5 days per week, for 9 weeks.
Study NCT04144491 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100ml of custard will be consumed 5 days per week, for 9 weeks.
Study NCT01419821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 800IU (4gtt/d) once a day for 2 years once a day.
Study NCT01419821 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Vitamin D)
Description: 4gtt/d for the placebo for two years.
Study NCT04357691 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Conventional training
Description: Participants will perform a conventional training for 4 weeks, using low-moderate-high-low intensity progression training model
Study NCT04357691 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: AI-led training
Description: Participants will perform an AI-led training for 4 weeks
Study NCT02555280 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: coflex® Interlaminar Technology
Description: Decompression plus coflex® Interlaminar Technology
Study NCT02555280 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompression
Description: Decompression alone
Study NCT00593580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00593580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alendronate/cholecalciferol
Description: FOSAVANCE (70 mg/2800 IU of alendronate and cholecalciferol) or placebo will be given weekly for 1 years duration
Study NCT01089361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.
Study NCT01089361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline placebo
Description: The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.
Study NCT03504137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Intervention
Description: The video DOT app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
Study NCT03993093 — intervention group
Intervention type: OTHER
Intervention: CD4 cell count
Description: CD4 cell count from treatment naive HIV patients
Study NCT04253509 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating Tumor DNA Methylation Sequencing
Description: Whole blood (21mL) collection through venipuncture. Analysis of tumor markers and ctDNA methylation sequencing.